LFVN

Lifevantage Corp

Nasdaq· Pharmaceutical Preparations· CIK 0000849146 Biotech & Drug Discovery

$5.76 −0.10 (−1.71%)

Oct 26 4:00 PM ET · prev $5.86

Market cap

$73.8M

Micro cap

Consensus

Buy

75% Buy or better · 8 analysts

Median target

$7.50

+30% · range $6.00–9.00

Next earnings

Nov 4

in 8 days · EPS est. $0.06

1 year

−32.3%

from $8.51 · Oct 28

30 days

−6.9%

from $6.19

52-week range

$4.02–10.70

−46% from high · low Apr 9

Avg volume 20D

29.5K

shares / day

Short interest

976.1K

≈7.8% of shares · −8.6%

Days to cover

28.8

at average volume

Insider net

+$135.1K

2 buyers · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BEARISH 3 reports · 90 days

Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/3 ·Next Earnings date, Nov 4, 2026

Strongest NEUTRAL Capital Management Corp /VA filed an amended Schedule 13G on 10/22/2026, reporting a 18.3% passive stake in…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 9 1 insider buy $20.7K at $5.22
B Feb 26 to Mar 2 3 days of insider buys: $152.4K by 1 insider, avg $4.59
B Mar 16 1 insider buy $5.5K at $5.23
A May 7 Lake Street downgrades
B Jun 15 1 insider buy $6.1K at $8.60
R Aug 27 LifeVantage reported Q4 FY2026 revenue of $42.4M (down 23.1% YoY) an…
S Sep 11 to Sep 14 2 days of insider sells: $55.6K by 1 insider, avg $6.18
B Sep 15 1 insider buy $6.1K at $6.22

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $190.7K at an average $4.78. 1 insider sold $55.6K. Price is 20% above their cost.
InstitutionsBEARISH

Q2 2026: 8 added (0 new), 15 trimmed or exited.
AnalystsBULLISH

6 of 8 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate $0.100 → $0.063 over 90 days. 0 up, 1 down in 30 days.
Short sellersSTEADY

Short interest −8.6% to 976.1K shares. 28.8 days to cover, ≈7.8% of shares.
TrendDOWNTREND

7% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	TRIM	268,605	$1.7M
AMERICAN CENTURY COMPANIES INC	ADD	144,386	$901.0K
GEODE CAPITAL MANAGEMENT, LLC	TRIM	120,830	$754.3K
GOLDMAN SACHS GROUP INC	TRIM	110,864	$691.8K
CITADEL ADVISORS LLC	ADD	99,791	$622.7K
MORGAN STANLEY	TRIM	65,284	$407.4K
STATE STREET CORP	TRIM	52,591	$328.2K
NORTHERN TRUST CORP	TRIM	24,978	$155.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 75% rate it Buy or better

Strong Buy2Buy4Hold2Sell0Strong Sell0

12-month targets · 2 analysts

$5.76 $6.00 $7.50 $9.00

Price is below the lowest target. Median implies +30%.Targets as of Oct 28, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 28, 2026	Lake Street MAINTAIN	MAINTAIN	Hold
May 7, 2026	Lake Street DOWNGRADE	DOWNGRADE	Hold

Insider ledger

Form 4

$190.7K

bought · 2 insiders

$55.6K

sold · 1 insider

+20.5%

vs their $4.78 cost

Date	Insider	Type	Value
Oct 7, 2026	Aure Carl Chief Financial Officer	AWARD	35,749 sh
Oct 7, 2026	Cunningham Kristen Chief Sales Officer	AWARD	32,850 sh
Oct 7, 2026	Moorehead Terrence President and CEO	AWARD	193,237 sh
Oct 7, 2026	Moorehead Terrence President and CEO	AWARD	289,855 sh
Oct 7, 2026	Cunningham Kristen Chief Sales Officer	AWARD	49,275 sh
Oct 7, 2026	Aure Carl Chief Financial Officer	AWARD	53,623 sh
Oct 1, 2026	Aure Carl Chief Financial Officer	TAX W/H	$2.9K
Oct 1, 2026	Cunningham Kristen Chief Sales Officer	TAX W/H	$4.0K

Earnings setup

Estimates

Nov 4

reports in 8 days

$0.06

EPS estimate, this quarter

−37%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

$0.100

90d

$0.100

60d

$0.100

30d

$0.100

$0.063

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	$0.06	$0.03–$0.10	-36.7%	$40.5M
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only